More threads by David Baxter PhD

David Baxter PhD

Late Founder
Depression Is a Dilemma for Women in Pregnancy
By RONI CARYN RABIN, New York Times
October 6, 2009

When Sherean Malekzadeh Allen of Marietta, Ga., learned she was pregnant, she was 43, had been married for two years, had gone through two miscarriages and had all but given up hope of having a baby.

But instead of being overjoyed, Ms. Allen was immobilized: panic-ridden, nauseated, listless and thoroughly depressed. She could not rouse herself to go to work in the marketing business she founded and ran, or even get through the newspaper.

And she faced the pregnant woman?s quintessential dilemma: take drugs that might pose a risk to the developing baby, or struggle through an anguishing pregnancy that could harm the baby in other ways?

?Every single thing you put in your body when you?re pregnant, you wonder, ?Oh, my God, am I growing my baby an extra finger?? ? Ms. Allen said. ?I was worried that I would hurt the baby if I took the pills, and I was worried I would hurt the baby if I didn?t.?

As many as a quarter of all pregnant women suffer from depression, and about an eighth use an antidepressant at some time during pregnancy, according to 2003 figures. Although many antidepressants appear to be fairly safe, studies have reported links between maternal use and a small increased risk of some fetal malformations. Other potential problems for the newborn include drug withdrawal and persistent pulmonary hypertension, which can impair blood flow to the lungs.

Recently, a Danish study in the British Medical Journal (BMJ) reported a link between pregnant women?s use of several antidepressants in the SSRI class, including Celexa and Zoloft, and an increased risk for a common heart defect in babies.

And a paper that appears Tuesday in the Archives of Pediatrics & Adolescent Medicine reports that babies born to mothers who use SSRI drugs were more likely to have low scores on the five-minute Apgar test, an overall measure of newborn health, and to be admitted to the neonatal intensive care unit.

To put such findings in perspective, experts from the American Psychiatric Association and the American College of Obstetricians and Gynecologists joined forces to review existing data and make recommendations for managing depression during pregnancy.

Their report, published in the September-October issue of General Hospital Psychiatry, finds that talk therapy should be the first-line treatment for mild to moderate depression, but it says that for severe cases the risks of antidepressants and even shock therapy are relatively low. Its main message, however, is that no generalizations apply: treatment decisions should be made case by case.

?There?s not a one-size-fits-all answer,? said Dr. Kimberly Yonkers, a professor of psychiatry and obstetrics and gynecology at Yale School of Medicine who was the report?s lead author, and who acknowledged receiving research support from antidepressant manufacturers. ?You can?t say, ?Stop medication for all women because it?s harmful,? and you can?t put all women on medication either.?

The tone of the report is generally reassuring but is filled with caveats. Because pregnant women are rarely recruited for clinical trials, research on drug effects during pregnancy is limited; there is no data from the kind of randomized controlled trials that scientists trust most. Much of the information comes from large epidemiological studies, many in Europe, that link patient databases; the analyses often cannot weed out or control for characteristics other than drugs that may be affecting the pregnancies.

The new report ? whose nine authors included four experts who acknowledged some financial, research or other ties to drug companies ? goes to great lengths to point out the inconsistencies in the findings about some of the more alarming drug associations.

It is also hard to weigh the risks of medication against those of an untreated depression. Studies have linked depression during pregnancy to premature births, growth changes, and irritability and inattention in the baby after birth. (Prenatal use of antidepressants has also been linked with premature birth, low birth weight and miscarriages.)

?Women have been having babies and taking these medications now for decades, and so far nothing striking has shown up,? said Dr. Nada Stotland, a recent president of the American Psychiatric Association.

Still, Dr. Stotland and other experts suggested that women who had a history of depression or were taking medication might want to consult a doctor before becoming pregnant rather than quit the drug on their own, which would put them at risk of a relapse.

In 2005, the Food and Drug Administration classified paroxetine, sold as Paxil, as a drug to be avoided during pregnancy after studies linked its use in the first trimester to an increased risk of heart defects in babies. The new paper says the agency based its action on data that were ?not strong,? but a number of studies have since found similar associations.

The Danish study reported that babies born to mothers who took Celexa (citalopram) and Zoloft (sertraline) were at double the risk of having septal heart defects, so-called holes in the heart. The absolute risk is still small, less than 1 percent, and the holes often close on their own. But the study noted that the risk was even higher if the mother took more than one kind of SSRI during her pregnancy.

Use of the same class of drugs late in pregnancy has been linked to an increased risk for persistent pulmonary hypertension, which can cause respiratory problems and serious complications in newborns. One recent study reported a sixfold increase in risk for the condition among babies born to mothers who used SSRI?s during the second half of pregnancy. But even with the use of drugs, the condition affects no more than 1.2 percent of babies, the report said.

A greater number of babies are affected by symptoms of drug withdrawal after birth: 15 to 30 percent of babies whose mothers used SSRI?s in late pregnancy experience effects like irritability, weak crying or no crying, abnormally fast breathing, hypoglycemia, unstable temperature and seizure. The symptoms usually resolve within two weeks.

Some critics said the paper gave short shrift to nondrug approaches like homeopathic remedies and nutritional supplements, while other experts said the paper?s endorsement of psychotherapy was ?politically correct? but ultimately unrealistic.

Dr. Shari I. Lusskin, director of reproductive psychiatry at N.Y.U. Langone Medical Center, said the real danger was undertreatment. ?By the time I get to hear about somebody?s perinatal depression,? Dr. Lusskin said, ?it?s usually worse than what can be treated with psychotherapy alone, because women go out of their way not to complain; they don?t want to be put on medication, and they feel guilty.

?We should use a low threshold for treating women aggressively.?

Ms. Allen, of Marietta, said she needed aggressive treatment, so she decided to take medication ? but was anxious about every pill. ?I would wait six or seven hours before taking the pill, and just work myself up into more of a state,? she recalled. ?My husband would say, ?That?s not good for the baby; don?t do that.? ?

Her son, Hunter Jamison Allen, was born at 9:05 p.m. on Election Day 2008, weighing 6 pounds 13 ounces, and scoring perfect Apgars. ?He?s happy, healthy and adorable,? Ms. Allen said. ?He?s my puddin? pop.?
 

David Baxter PhD

Late Founder
New Report on the Use of Antidepressants During Pregnancy
By Jennifer Gibson, PharmDcloseJennifer Gibson, PharmD
October 06, 2009

Depression is a major health concern worldwide, and is the second leading cause of disability for people of reproductive age (15 to 44 years), according to the World Health Organization. Women experience depression two to three times more frequently than men. Depression can be devastating for these women in general, but it can lead to significant consequences when experienced before and during pregnancy. A new report, published jointly by the American Psychiatric Association (APA) and the American College of Obstetrics and Gynecology (ACOG), evaluates and summarizes the risks associated with depression and antidepressant therapy during pregnancy, and offers new guidelines for treatment decisions. On the whole, the report advises that many women consider discontinuing therapy with antidepressants before and during pregnancy.

Increasing attention has been paid to postpartum depression (PPD) in recent years. It is estimated that up to 16% of women will experience symptoms of depression in the first year after giving birth. PPD carries considerable emotional, physical, and psychological consequences for the mother and the child, but many researchers and clinicians now suggest than antenatal depression (depression during pregnancy) might be even more problematic. Nearly one-quarter of women experience antenatal depression, though maternal depression (both in the pre- and postnatal periods) is likely underdiagnosed. Maternal depression can lead to poor maternal self-care, increased risk-taking behavior, and poor pregnancy outcomes, including pre-eclampsia, birth difficulties for both mother and child, increased risk for PPD, and reduced breastfeeding. For the newborn, maternal depression can lead to lower APGAR (American Pediatric Gross Assessment Record) scores at birth, failure to thrive, and poor physical, emotional, and behavioral development. However, the interplay among these factors is unclear and a combination of factors likely influences maternal and child outcomes; while maternal depression does influence infant outcomes, poor infant outcomes can lead to maternal depression.

Signs and symptoms associated with antenatal depression are the same as those for depression in the general population: depressed mood, anhedonia, low self esteem, changes in sleep or appetite, decreased energy, and decreased concentration. The diagnosis of antenatal depression can be difficult, since there are no specific diagnostic criteria for depression during pregnancy; also, the normal symptoms of pregnancy overlap with symptoms of depression, making identification of depression problematic. Women and clinicians often attribute fatigue, decreased energy, appetite changes, and altered concentration to a normal, healthy pregnancy rather than a depressive disorder. On the other hand, researchers or clinicians who rely on questionnaires assessing somatic symptoms during pregnancy may overdiagnose depressive disorders in pregnant women. The risk factors for antenatal depression involve genetic and environmental factors. A genetic predisposition to depression can be affected by physical, mental, or emotional stress, infections, chronic diseases, medication use, lack of social support, low socioeconomic status, and poor nutrition.

Overall the APA/ACOG review reports that symptoms of depression and antidepressant use during pregnancy may be associated with preterm delivery, decreased fetal growth, and developmental changes in the child, but states that current research is inconclusive. Most studies were unable to control for confounding maternal factors such as maternal illness or high-risk health behaviors that affect pregnancy outcomes. However, due to the potentially damaging consequences of antidepressant use, the report recommends that some women who are pregnant or considering becoming pregnant taper or discontinue therapy to mitigate these risks.

Women who have experienced mild or no depressive symptoms for 6 months should consider discontinuing treatment with antidepressants before becoming pregnant. These women may benefit from psychotherapy during the treatment hiatus. Patients with suicidal or acute psychotic symptoms should optimize their therapy and be counseled to wait several months after adjusting therapy before conceiving. For these patients, the risks associated with untreated depressive symptoms often outweigh the potential harm to the unborn child. Antiepileptic agents, sometimes used to treat severe symptoms of depression and psychosis, should be avoided, if at all possible, during the first trimester of pregnancy owing to the risk of birth defects. Largely, women with depression before or during pregnancy should consider alternative treatment, according to the APA and ACOG, since reproductive safety information for antidepressants is lacking.

Close monitoring of pregnant women with depression is advised, and no treatment decision should be made without consulting a trained clinician. The risks and benefits of treatment ? both to the mother and the child ? should be weighed to ensure a safe and healthy pregnancy. Additional research is still needed to define the best possible treatment regimens for pregnant women.

References

  1. Gavin, A., Holzman, C., Siefert, K., & Tian, Y. (2009). Maternal Depressive Symptoms, Depression, and Psychiatric Medication Use in Relation to Risk of Preterm Delivery. Women?s Health Issues, 19 (5), 325-334
  2. Leung, B., & Kaplan, B. (2009). Perinatal Depression: Prevalence, Risks, and the Nutrition Link - A Review of the Literature. Journal of the American Dietetic Association, 109 (9), 1566-1575
  3. Salisbury, A., Ponder, K., Padbury, J., & Lester, B. (2009). Fetal Effects of Psychoactive Drugs. Clinics in Perinatology, 36 (3), 595-619
  4. Yonkers, K. (2009). Parsing Risk for the Use of Selective Serotonin Reuptake Inhibitors in Pregnancy. American Journal of Psychiatry, 166 (3), 268-270
  5. Yonkers, K., Smith, M., Gotman, N., & Belanger, K. (2009). Typical somatic symptoms of pregnancy and their impact on a diagnosis of major depressive disorder. General Hospital Psychiatry, 31 (4), 327-333
  6. Yonkers, K., Wisner, K., Stewart, D., Oberlander, T., Dell, D., Stotland, N., Ramin, S., Chaudron, L., & Lockwood, C. (2009). The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. General Hospital Psychiatry, 31 (5), 403-413
 
Replying is not possible. This forum is only available as an archive.
Top